Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study
Recruiting
Observational Study
Breast Adenocarcinoma
Breast Cancer Stage IV
Breast Cancer, Metastatic
Breast Carcinoma
Breast Diseases
Breast Neoplasms
Breast Neoplasms, Male
Breast Cancer
Breast Cancer With Metastatic Bone Disease
Breast Cancers
Breast Neoplasm
Breast Tumors
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
HR+ Advanced or Metastatic Breast Cancer
HR+/HER2- Breast Cancer
HRpos Breast Neoplasms
HR-positive, HER2-negative Advanced Breast Cancer
HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
HR-positive Breast Cancer
Hormone Receptor-Positive Breast Cancer
Hormone Receptor Positive Breast Adenocarcinoma
Hormone Receptor Positive Breast Carcinoma
Hormone Receptor Positive Breast Neoplasms
Hormone Receptor Positive HER-2 Negative Breast Cancer
Hormone Receptor Positive Malignant Neoplasm of Breast
Hormone Receptor Positive Metastatic Breast Cancer
Hormone Receptor Positive, HER2 Negative Breast Cancer
Hormone Receptor Negative Breast Cancer
Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer
Hormone Receptor Positive Breast Cancer
Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Hormone Receptor Positive, HER2-negative Neoplasms
Hormone Receptor Positive, HER2-low Neoplasms
Hormone Receptor Positive (HR+), HER2-negative Breast Cancer
Hormone Receptor (HR)-Positive Breast Cancer
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Palbociclib
Ribociclib
Abemaciclib
CDK4/6 Inhibitor
CDK4/6 Inhibitors
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,500 (estimated)
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
PALMARES-2 is a retrospective/prospective, observational, multicenter, population-based study, aiming at providing real-world evidences on HR+/HER2- aBC patients treated with first-line CDK4/6i plus ET. The present study has the objective to collect data coming from different sources, i.e. RWD, medical images and biological samples, from patients treated with CDK4/6i as first-line of therapy for H…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of HR+/HER2- advanced Breast Cancer (aBC), as defined as at least 1% estrogen receptor (ER) and/or progesterone receptor (PgR) positivity at IHC. HER2 negativity is defined on the basis of an IHC score of 0, 1+, or 2+ with absence of gene amplification at in situ hyb…
Contacts